Literature DB >> 9776479

Individual variations in lymphocyte-responses to glucocorticoids in patients with bronchial asthma: comparison of potencies for five glucocorticoids.

T Hirano1, M Homma, K Oka, H Tsushima, T Niitsuma, T Hayashi.   

Abstract

Glucocorticoids (GCs) are known to be effective for bronchial asthma, however, a considerable number of asthma patients fail to respond to GC despite the onset of serious side effects. Here we examined individual sensitivities to five clinically-used GCs in 40 asthma patients and 100 healthy subjects. Peripheral-blood mononuclear cells (PBMCs) were isolated from these subjects, and their in vitro sensitivities to hydrocortisone, prednisolone, methylprednisolone, dexamethasone, and betamethasone were determined with a mitogen-assay procedure. The number of PBMCs positive to IL-2 receptors (IL-2Rs) as well as soluble IL-2R (sIL-2R) levels in serum were concomitantly measured in asthma patients, and relationships between these cytokine indices and PBMC-sensitivities to GCs were also examined. Large individual variations in GC IC50s have been observed in PBMCs from asthma subjects, especially in prednisolone IC50s (ranged from 1 to 10,000 ng/ml). When compared with healthy subjects, asthma patients tend to show PBMC-resistance to prednisolone (p < 0.05). Moreover, potencies of methylprednisolone on PBMC-blastogenesis were > 10 times higher than those of prednisolone in both healthy subjects and asthmatics (p < 0.01). In asthma patients, IC50s of hydrocortisone, prednisolone and betamethasone against PBMC-blastogenesis were significantly correlated with elevated percentages of IL-2R-positive PBMCs (p < 0.05), while the IC50 of methylprednisolone showed no such correlation. sIL-2R levels did not correlate with IC50s of any of the GCs examined. Thus, the results showed that a part of asthma patients exhibited PBMC-resistance to GCs, especially to prednisolone. Methylprednisolone potency was unexpectedly higher (> 10 times) than prednisolone potency. Our results also raised the possibility that PBMC-resistance to prednisolone in asthma may correlate with an increase in IL-2R positive PBMCs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9776479     DOI: 10.1016/s0162-3109(98)00025-3

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  5 in total

1.  Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone.

Authors:  Eva Cuzzoni; Sara De Iudicibus; Fiora Bartoli; Alessandro Ventura; Giuliana Decorti
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

2.  Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.

Authors:  Keivan Ranjbar; Mohsen Moghadami; Alireza Mirahmadizadeh; Mohammad Javad Fallahi; Vahid Khaloo; Reza Shahriarirad; Amirhossein Erfani; Zohre Khodamoradi; Mohammad Hasan Gholampoor Saadi
Journal:  BMC Infect Dis       Date:  2021-04-10       Impact factor: 3.090

3.  Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients.

Authors:  Mohammed Abdel Monem Saeed; Alaa Hussein Mohamed; Ahmed Hassan Owaynat
Journal:  Egypt J Intern Med       Date:  2022-02-15

Review 4.  Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review.

Authors:  Jyoti Mehta; Rajan Rolta; Brij Bhushan Mehta; Neha Kaushik; Eun Ha Choi; Nagendra Kumar Kaushik
Journal:  Front Microbiol       Date:  2022-02-15       Impact factor: 5.640

5.  Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone.

Authors:  Alessandro Russo; Chiara Davoli; Cristian Borrazzo; Vincenzo Olivadese; Giancarlo Ceccarelli; Paolo Fusco; Alessandro Lazzaro; Rosaria Lionello; Marco Ricchio; Francesca Serapide; Bruno Tassone; Elio Gentilini Cacciola; Claudio Maria Mastroianni; Carlo Torti; Gabriella d'Ettorre; Enrico Maria Trecarichi
Journal:  Biomedicines       Date:  2022-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.